Supernus, Indivior merge to strengthen neuroscience drug portfolio

Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that ​would create a company with about $2.2 billion ‌in annual revenue and a portfolio of m...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。